Premium
Suppression of plasma matrix metalloproteinase‐9 following montelukast treatment in childhood asthma
Author(s) -
CHUANG SHIHSUNG,
HUNG CHIHHSING,
HUA YIMING,
TIEN CHIUNGHSI,
YANG KUENDER D,
JONG YUHJYH,
HSU SHIHHSIEN,
LIN CHANGSHEN
Publication year - 2007
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.2007.02497.x
Subject(s) - montelukast , medicine , ketotifen , asthma , exhaled nitric oxide , matrix metalloproteinase 9 , leukotriene , matrix metalloproteinase , gastroenterology , inflammation , anesthesia , immunology , spirometry
Background: Montelukast and ketotifen are commonly prescribed anti‐inflammatory medications used in the treatment of childhood asthma. Methods: To investigate the modulation effect of montelukast and ketotifen, the levels of exhaled nitric oxide (eNO) and plasma matrix metalloproteinase‐9 (MMP‐9) were analyzed in a group of 30 children with mild persistent asthma. Results: Patients on montelukast therapy for 8 weeks had significantly decreased levels of eNO and plasma MMP‐9, which were associated with improved symptoms and enhanced peak expiratory flow but not significantly associated with increased level of tissue inhibitor metalloproteinase‐1 (TIMP‐1). In contrast, treatment with ketotifen produced no significant changes in these parameters until 4–6 weeks into the therapy and no effect on plasma MMP‐9. Conclusion: Leukotriene antagonists, such as montelukast, may be better non‐steroidal anti‐inflammatory drugs for preventing airway inflammation in mild childhood asthma.